Antibody Drug Conjugates Market

Antibody Drug Conjugates Market Revenue Predicted to Go Up by 2024
Antibody drug conjugates are defined as the monoclonal antibodies attached with biologically
active drugs by chemical linkers through labile bonds. By combining the targeting ability of
molecular antibodies with cancer ability of cytotoxic drugs, antibody drug conjugates allows
targeted therapy for the treatment of cancer patients. They allow sensitive discrimination between
healthy and cancerous tissues.
Report Overview and TOC @
The market for antibody drug conjugate is in infancy stage. So far, only three antibody drug
conjugates have received market approval from the U.S. Food and Drug Administration (FDA).
However, the first among them, Mylotarg was withdrawn from the market by its manufacturer
Wyeth, Inc., group company of Pfizer, Inc. in June 2010. Myotarg was used to treat acute
myelogenous leukemia but a clinical trial showed that the drug has accelerated the mortality rate
among the myelogenous leukemia patients and had added no benefits over conventional cancer
therapies. Therefore, the market for antibody drug conjugates can be segmented on the basis of
other two approved drugs which include:
Adcertis (Brentuximab vedotin) is an antibody drug conjugate directed to the protein CD30 which is
expressed in Hodgkin lymphoma and systemic anaplastic large cell lymphoma. In February 2011,
Seattle Genetics submitted Biologics License Application (BLA) to the U.S. FDA for use in
relapsed or refractory Hodgkin’s lymphoma and refractory or relapsed anaplastic large cell
lymphoma. The drug was granted accelerated approval by the U.S. FDA in August 2011. Adcertis
dominated the antibody drug conjugate market as only approved drug from August 2011 till
February 2013. The drug also received marketing authorization from the European Medicines
Agency in October 2012.
Request brochure @
Kadcyla (Trastuzumab emtansine) is an antibody drug conjugate consisting of the monoclonal
antibody trastuzumab linked to cytotoxic agent mertansine DM1. In the Emilia (Italy) clinical trials
of women suffering from HER2 positive breast cancer who were only resistant to trastuzumab
alone, kadcyla improved survival by 5.8 months. Based on this trial, the drug received approval
from U.S. FDA in February 2013. Kadcyla was developed by Genentech, Inc., a subsidiary of F.
Hoffmann-La Roche AG and is manufactured by Lonza group. The introduction of kadcyla assisted
the antibody drug conjugate market in its steep growth from 2012 to 2013.
for Specific and Customized [email protected]
Extensive research and development is the major factor which is driving the antibody drug
conjugate market. Majority of the antibody drug conjugates under development are for oncological
indications propelled by the availability of monoclonal antibodies targeting different types of
cancer. Some market players are also looking outside the oncology domain to develop antibody
drug conjugate, though, such drugs are limited in number are in preclinical stage of development.
As the large number of large pharmaceutical companies are now involved in antibody drug
conjugates market, therefore it is expected that this market will grow rapidly during the forecast
period. More than thirty antibody drug conjugates are under pipeline currently, among which
Inotuzumab Ozogamicin by Pfizer, Inc., Glembatumumab Vedotin by Celldex Therapeutics,
Lorvotuzumab Mertansine by ImmunoGen, Inc., SAR3419 by Sanofi S.A. and PSMA-ADC by
Progenics Pharmaceuticals are currently under phase II clinical trials. However, the high cost
associated with research activities and sunk cost involved in R&D activities restrains the antibody
drug conjugates market. Other players which are involved in research activities of antibody drug
conjugates development include Biotest Pharmaceuticals Corporation, Bayer AG, Synthon BV and
Immunomedics, Inc.
Pre Book full [email protected]